Literature DB >> 15839719

Hypertension in the elderly: a Japanese perspective.

Toshio Ogihara1, Hiromi Rakugi.   

Abstract

Elderly individuals with hypertension show specific characteristics as a result of advancing arteriosclerosis, a high frequency of isolated systolic hypertension, increased pulse pressure and orthostatic hypotension. The necessity to treat hypertension in the elderly, including isolated systolic hypertension, has been demonstrated in many large-scale intervention trials. Young-old (65-74 years of age) hypertensive patients should be treated the same as nonelderly hypertensive patients. In old-old (75-84 years of age) patients with mild hypertension (140-159/90-99 mm Hg), the recommended target blood pressure (BP) is <140/90 mm Hg. In old-old (75-84 years of age) and oldest-old (> or =85 years of age) patients with systolic BP > or =160 mm Hg, cautious treatment is required. An intermediate target BP of <150 mm Hg is appropriate, followed by a final target BP of <140 mm Hg, if tolerated. Nonmedical therapy, such as salt restriction, exercise and weight reduction, is useful in the elderly. However, individualised management of nonmedical therapy is necessary to avoid deterioration of quality of life resulting from strict management of the patient's lifestyle. Diuretics, calcium channel antagonists, ACE inhibitors and angiotensin II type 1 receptor antagonists have been established as first-line antihypertensive drugs in the elderly. Use of combination therapy helps to achieve target BPs. The starting dose of each drug should be half the usual dose for nonelderly patients, and may be increased at intervals of >4 weeks, with achievement of the target BP in 3-6 months or longer. In hypertensive patients with co-morbid diseases, the target BP should be determined individually and antihypertensive drugs selected bearing in mind the patient's clinical circumstances. Avoiding hypoperfusion of target organs is very important in elderly hypertensive patients. When treating hypertension in elderly patients, the approach should be to identify individual pathophysiological characteristics and lower the BP cautiously and slowly.

Entities:  

Mesh:

Year:  2005        PMID: 15839719     DOI: 10.2165/00002512-200522040-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  103 in total

1.  Guidelines for the management of hypertension for general practitioners.

Authors: 
Journal:  Hypertens Res       Date:  2001-11       Impact factor: 3.872

2.  Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects.

Authors: 
Journal:  Am J Cardiol       Date:  2004-04-15       Impact factor: 2.778

Review 3.  Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Part 1.

Authors:  G Tsujimoto; K Hashimoto; B B Hoffman
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-01

4.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

6.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.

Authors:  S S Franklin; S A Khan; N D Wong; M G Larson; D Levy
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Alcohol drinking and high blood pressure: data from a 1980 national cardiovascular survey of Japan.

Authors:  H Ueshima; H Ozawa; S Baba; Y Nakamoto; T Omae; T Shimamoto; Y Komachi
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

9.  Inhibition of angiotensin-converting enzyme modulates the autoregulation of regional cerebral blood flow in hypertensive rats.

Authors:  S Sadoshima; T Nagao; S Ibayashi; M Fujishima
Journal:  Hypertension       Date:  1994-06       Impact factor: 10.190

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  2 in total

1.  Effects of a mat pilates program on cardiometabolic parameters in elderly women.

Authors:  Fourie Marinda; Gildenhuys Magda; Shaw Ina; Shaw Brandon; Toriola Abel; Daniel Ter Goon
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

2.  Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.

Authors:  Artavazd Tadevosyan; Eric J Maclaughlin; Vardan T Karamyan
Journal:  Patient Relat Outcome Meas       Date:  2011-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.